Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S (NVO) of a Class Action Lawsuit and an Upcoming Deadline

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S due to alleged securities fraud affecting investors between November 2, 2022, and December 19, 2024 [1] Group 1: Lawsuit Details - The lawsuit is in response to Novo's press release on December 20, 2024, which disclosed below-expected results from the "REDEFINE 1" trial, where patients treated with CagriSema lost only 22.7% of their weight after 68 weeks, falling short of the targeted 25% [2] - The trial allowed participants to modify their dosage, resulting in only 57.3% of patients receiving the highest dosage intended for the study [2] - Following the announcement, Novo's stock price dropped by $18.44, closing at$85.00 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]